Alnylam Historical Balance Sheet

ALNY Stock

USD 268.46 2.56 0.94%

Trend analysis of Alnylam Pharmaceuticals balance sheet accounts such as Other Current Liab of 1.1 B, Total Current Liabilities of 1.2 B or Total Stockholder Equity of 63.7 M provides information on Alnylam Pharmaceuticals' total assets, liabilities, and equity, which is the actual value of Alnylam Pharmaceuticals to its prevalent stockholders. By breaking down trends over time using Alnylam Pharmaceuticals balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Alnylam Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Alnylam Pharmaceuticals is a good buy for the upcoming year.

Alnylam Pharmaceuticals Inventory

82.43 Million

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Alnylam Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

For more information on how to buy Alnylam Stock please use our How to Invest in Alnylam Pharmaceuticals guide.

About Alnylam Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Alnylam Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Alnylam Pharmaceuticals Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Alnylam Pharmaceuticals and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Alnylam currently owns. An asset can also be divided into two categories, current and non-current.

Alnylam Pharmaceuticals Balance Sheet Chart

At this time, Alnylam Pharmaceuticals' Liabilities And Stockholders Equity is fairly stable compared to the past year. Non Current Liabilities Total is likely to rise to about 3.1 B in 2025, whereas Total Stockholder Equity is likely to drop slightly above 63.7 M in 2025.

Total Assets Other Current Liab Total Current Liabilities Property Plant And Equipment Net

Add Fundamental

Total Assets

Total assets refers to the total amount of Alnylam Pharmaceuticals assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Alnylam Pharmaceuticals books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Alnylam Pharmaceuticals balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Alnylam Pharmaceuticals are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Property Plant And Equipment Net

The total value of a company's physical assets (such as land, buildings, and equipment) used in operations, net of depreciation. It reflects the company's investment in assets used for production.

Most accounts from Alnylam Pharmaceuticals' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Alnylam Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Alnylam Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

For more information on how to buy Alnylam Stock please use our How to Invest in Alnylam Pharmaceuticals guide.At this time, Alnylam Pharmaceuticals' Liabilities And Stockholders Equity is fairly stable compared to the past year. Non Current Liabilities Total is likely to rise to about 3.1 B in 2025, whereas Total Stockholder Equity is likely to drop slightly above 63.7 M in 2025.

	2022	2023	2024	2025 (projected)
Other Current Liabilities	545.5M	713.0M	1.0B	1.1B
Total Assets	3.5B	3.8B	4.2B	4.5B

Other Current Liab Total Assets

Alnylam Pharmaceuticals balance sheet Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Other Current Assets	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Property Plant Equipment	Short Long Term Debt Total	Other Liab	Current Deferred Revenue	Long Term Debt	Other Stockholder Equity
Total Assets		0.9	0.94	-0.15	0.94	0.39	-0.98	0.89	0.29	0.93	-0.08	0.76	0.98	0.79	0.97	0.9	0.36	0.93	0.97	0.99	0.96	0.78	0.67	0.26	0.88	0.47
Other Current Liab	0.9		0.85	-0.45	0.82	0.44	-0.93	0.82	-0.01	0.82	-0.11	0.75	0.86	0.54	0.87	0.95	0.21	0.95	0.94	0.9	0.88	0.82	0.53	-0.01	0.94	0.1
Total Current Liabilities	0.94	0.85		-0.19	0.96	0.42	-0.92	0.81	0.13	0.95	0.02	0.64	0.88	0.71	0.93	0.84	0.43	0.89	0.94	0.9	0.94	0.71	0.76	0.5	0.8	0.42
Total Stockholder Equity	-0.15	-0.45	-0.19		-0.18	-0.63	0.29	-0.15	0.38	-0.17	0.17	-0.26	-0.05	0.19	-0.15	-0.56	0.03	-0.49	-0.33	-0.13	-0.19	-0.56	-0.2	0.33	-0.55	0.26
Property Plant And Equipment Net	0.94	0.82	0.96	-0.18		0.51	-0.95	0.87	0.21	0.96	-0.05	0.67	0.88	0.77	0.95	0.86	0.44	0.9	0.95	0.9	0.98	0.75	0.71	0.43	0.83	0.58
Net Debt	0.39	0.44	0.42	-0.63	0.51		-0.52	0.32	-0.12	0.46	-0.41	0.44	0.3	0.28	0.48	0.6	0.2	0.57	0.54	0.35	0.46	0.78	0.34	0.09	0.58	0.42
Retained Earnings	-0.98	-0.93	-0.92	0.29	-0.95	-0.52		-0.91	-0.21	-0.92	0.15	-0.78	-0.94	-0.77	-0.96	-0.95	-0.3	-0.96	-0.99	-0.96	-0.98	-0.85	-0.65	-0.18	-0.94	-0.46
Accounts Payable	0.89	0.82	0.81	-0.15	0.87	0.32	-0.91		0.16	0.84	0.03	0.87	0.87	0.75	0.87	0.82	0.22	0.84	0.88	0.88	0.92	0.64	0.6	0.1	0.84	0.42
Cash	0.29	-0.01	0.13	0.38	0.21	-0.12	-0.21	0.16		0.12	-0.36	0.04	0.39	0.51	0.15	0.11	0.0	0.11	0.12	0.34	0.14	0.21	0.23	0.16	0.11	0.65
Non Current Assets Total	0.93	0.82	0.95	-0.17	0.96	0.46	-0.92	0.84	0.12		0.11	0.66	0.85	0.73	0.92	0.83	0.6	0.88	0.94	0.87	0.95	0.69	0.62	0.43	0.77	0.5
Non Currrent Assets Other	-0.08	-0.11	0.02	0.17	-0.05	-0.41	0.15	0.03	-0.36	0.11		-0.08	-0.15	-0.1	-0.07	-0.19	0.4	-0.13	-0.11	-0.15	-0.06	-0.48	-0.04	0.21	-0.24	-0.24
Other Assets	0.76	0.75	0.64	-0.26	0.67	0.44	-0.78	0.87	0.04	0.66	-0.08		0.75	0.6	0.74	0.75	0.03	0.76	0.75	0.76	0.73	0.67	0.49	-0.07	0.81	0.26
Cash And Short Term Investments	0.98	0.86	0.88	-0.05	0.88	0.3	-0.94	0.87	0.39	0.85	-0.15	0.75		0.8	0.94	0.85	0.24	0.88	0.92	1.0	0.91	0.75	0.66	0.21	0.85	0.46
Common Stock Shares Outstanding	0.79	0.54	0.71	0.19	0.77	0.28	-0.77	0.75	0.51	0.73	-0.1	0.6	0.8		0.75	0.59	0.32	0.63	0.71	0.78	0.76	0.57	0.53	0.39	0.58	0.71
Short Term Investments	0.97	0.87	0.93	-0.15	0.95	0.48	-0.96	0.87	0.15	0.92	-0.07	0.74	0.94	0.75		0.87	0.36	0.91	0.96	0.95	0.97	0.76	0.7	0.3	0.85	0.47
Non Current Liabilities Total	0.9	0.95	0.84	-0.56	0.86	0.6	-0.95	0.82	0.11	0.83	-0.19	0.75	0.85	0.59	0.87		0.23	0.99	0.94	0.89	0.88	0.91	0.61	0.03	0.99	0.29
Other Current Assets	0.36	0.21	0.43	0.03	0.44	0.2	-0.3	0.22	0.0	0.6	0.4	0.03	0.24	0.32	0.36	0.23		0.3	0.38	0.25	0.37	0.15	0.17	0.47	0.1	0.34
Total Liab	0.93	0.95	0.89	-0.49	0.9	0.57	-0.96	0.84	0.11	0.88	-0.13	0.76	0.88	0.63	0.91	0.99	0.3		0.97	0.92	0.91	0.89	0.67	0.11	0.97	0.32
Property Plant And Equipment Gross	0.97	0.94	0.94	-0.33	0.95	0.54	-0.99	0.88	0.12	0.94	-0.11	0.75	0.92	0.71	0.96	0.94	0.38	0.97		0.94	0.98	0.85	0.67	0.22	0.92	0.4
Total Current Assets	0.99	0.9	0.9	-0.13	0.9	0.35	-0.96	0.88	0.34	0.87	-0.15	0.76	1.0	0.78	0.95	0.89	0.25	0.92	0.94		0.93	0.78	0.67	0.19	0.89	0.44
Property Plant Equipment	0.96	0.88	0.94	-0.19	0.98	0.46	-0.98	0.92	0.14	0.95	-0.06	0.73	0.91	0.76	0.97	0.88	0.37	0.91	0.98	0.93		0.75	0.67	0.3	0.86	0.48
Short Long Term Debt Total	0.78	0.82	0.71	-0.56	0.75	0.78	-0.85	0.64	0.21	0.69	-0.48	0.67	0.75	0.57	0.76	0.91	0.15	0.89	0.85	0.78	0.75		0.52	0.01	0.9	0.4
Other Liab	0.67	0.53	0.76	-0.2	0.71	0.34	-0.65	0.6	0.23	0.62	-0.04	0.49	0.66	0.53	0.7	0.61	0.17	0.67	0.67	0.67	0.67	0.52		0.48	0.61	0.43
Current Deferred Revenue	0.26	-0.01	0.5	0.33	0.43	0.09	-0.18	0.1	0.16	0.43	0.21	-0.07	0.21	0.39	0.3	0.03	0.47	0.11	0.22	0.19	0.3	0.01	0.48		-0.04	0.49
Long Term Debt	0.88	0.94	0.8	-0.55	0.83	0.58	-0.94	0.84	0.11	0.77	-0.24	0.81	0.85	0.58	0.85	0.99	0.1	0.97	0.92	0.89	0.86	0.9	0.61	-0.04		0.26
Other Stockholder Equity	0.47	0.1	0.42	0.26	0.58	0.42	-0.46	0.42	0.65	0.5	-0.24	0.26	0.46	0.71	0.47	0.29	0.34	0.32	0.4	0.44	0.48	0.4	0.43	0.49	0.26

Click cells to compare fundamentals

Alnylam Pharmaceuticals Account Relationship Matchups

Alnylam Pharmaceuticals balance sheet Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	3.4B	3.6B	3.5B	3.8B	4.2B	4.5B
Other Current Liab	355.9M	395.2M	545.5M	713.0M	1.0B	1.1B
Total Current Liabilities	1.1B	1.2B	767.9M	967.8M	1.2B	1.2B
Total Stockholder Equity	1.0B	588.2M	(158.2M)	(220.6M)	67.1M	63.7M
Property Plant And Equipment Net	706.5M	733.6M	738.6M	725.8M	693.9M	728.6M
Net Debt	24.6M	177.6M	453.9M	1.9B	(127.1M)	(133.5M)
Retained Earnings	(4.6B)	(5.4B)	(6.6B)	(7.0B)	(7.3B)	(6.9B)
Accounts Payable	52.0M	73.4M	98.1M	55.5M	88.4M	92.8M
Cash	496.6M	820.0M	866.4M	812.7M	127.1M	120.8M
Non Current Assets Total	1.2B	774.5M	854.1M	847.2M	944.7M	991.9M
Non Currrent Assets Other	500M	40.9M	115.5M	(576.4M)	133.9M	140.6M
Other Assets	32.9M	40.7M	101.1M	115.5M	132.8M	139.4M
Cash And Short Term Investments	1.9B	2.4B	2.2B	2.4B	2.7B	2.8B
Common Stock Shares Outstanding	115.0M	118.5M	121.7M	124.9M	128.6M	73.5M
Short Term Investments	1.4B	1.6B	1.3B	1.6B	1.7B	1.8B
Liabilities And Stockholders Equity	3.4B	3.6B	3.5B	3.8B	4.2B	4.5B
Non Current Liabilities Total	1.3B	1.9B	2.9B	3.1B	3.0B	3.1B
Other Current Assets	625.5M	88.1M	132.9M	126.4M	117.0M	96.0M
Total Liab	2.4B	3.1B	3.7B	4.1B	4.2B	4.4B
Property Plant And Equipment Gross	706.5M	733.6M	738.6M	948.9M	964.3M	1.0B
Total Current Assets	2.2B	2.9B	2.7B	3.0B	3.3B	3.5B
Accumulated Other Comprehensive Income	(43.6M)	(33.3M)	(44.7M)	(23.4M)	(21.0M)	(20.0M)
Property Plant Equipment	425.2M	465.0M	502.0M	523.5M	602.0M	632.1M
Short Long Term Debt Total	521.2M	997.6M	1.3B	2.7B	1.3B	1.4B
Other Liab	327.7M	352.3M	1.4B	406.4M	467.3M	490.7M
Current Deferred Revenue	352.3M	301.8M	42.1M	102.8M	55.5M	52.7M
Other Stockholder Equity	5.6B	6.1B	6.5B	6.8B	65.8M	62.5M
Short Term Debt	50.2M	77.6M	82.3M	96.5M	41.9M	42.6M
Net Receivables	102.4M	198.6M	238.0M	327.8M	405.3M	425.6M
Common Stock Total Equity	1.1M	1.2M	1.2M	1.2M	1.4M	770.9K
Common Stock	1.2M	1.2M	1.2M	1.3M	1.3M	831.2K
Net Tangible Assets	1.4B	1.0B	588.2M	(158.2M)	(182.0M)	(172.9M)
Retained Earnings Total Equity	(3.7B)	(4.6B)	(5.4B)	(6.6B)	(5.9B)	(5.6B)
Capital Surpluse	5.2B	5.6B	6.1B	6.5B	7.4B	7.8B
Inventory	92.3M	122.7M	129.0M	89.1M	78.5M	82.4M
Non Current Liabilities Other	1.6B	1.7B	1.5B	1.6B	1.7B	1.8B

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ZLAB	Zai Lab
ASLE	AerSale Corp
ATS	AT S Austria

Additional Tools for Alnylam Stock Analysis

When running Alnylam Pharmaceuticals' price analysis, check to measure Alnylam Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alnylam Pharmaceuticals is operating at the current time. Most of Alnylam Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Alnylam Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alnylam Pharmaceuticals' price. Additionally, you may evaluate how the addition of Alnylam Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Alnylam Historical Balance Sheet

Alnylam Pharmaceuticals Inventory

82.43 Million

About Alnylam Balance Sheet Analysis

Alnylam Pharmaceuticals Balance Sheet Chart

Total Assets

Total Current Liabilities

Property Plant And Equipment Net

Alnylam Pharmaceuticals balance sheet Correlations

Alnylam Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Alnylam Pharmaceuticals balance sheet Accounts

Also Currently Popular

Additional Tools for Alnylam Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Cash And Short Term Investments
Total Current Assets	+ 0.99	Total Assets
Total Liab	+ 0.99	Non Current Liabilities Total
Long Term Debt	+ 0.99	Non Current Liabilities Total
Cash And Short Term Investments	+ 0.98	Total Assets
Property Plant Equipment	+ 0.98	Property Plant And Equipment Net

Property Plant And Equipment Gross	- 0.99	Retained Earnings
Property Plant Equipment	- 0.98	Retained Earnings
Retained Earnings	- 0.98	Total Assets
Total Current Assets	- 0.96	Retained Earnings
Total Liab	- 0.96	Retained Earnings
Short Term Investments	- 0.96	Retained Earnings